We are pleased to share materials from the recent May CiPA Update meeting, "The Future of the Assessment of Drug-Induced Arrhythmias and CiPA.”
SOT CCT Meeting: The Use of Cardiomyocytes for the Assessment of Proarrhythmic Risk
Evaluation of HTS Platforms for Assessing Drug Effects on Cardiac Currents
Please consider joining this HESI-sponsored effort to assess the variability and reproducibility of high throughput screening platforms/sites for defining drug effects on cardiac ionic currents across and between platforms
Dear SPS Members,
The HESI Cardiac Safety Proarrhythmia Working Group is embarking on a new initiative to better understand high-throughput automated patch clamp systems. HESI is creating an ‘HTS Subteam’ to further scope and carry-out a pilot study. Specifically, the goal of the study is to asses
The Safety Pharmacology Society is pleased to invite you to a webinar on Comprehensive In Vitro Proarrhythmia Assay (CiPA): An Update from An Industry Perspective on April 16, at 11:00 am ET.
Title: Defining the CiPA Paradigm: An Update from the Ion Channel Working Group (IC